Published in Eur Heart J on February 24, 2010
Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study. J Interv Cardiol (2014) 0.94
Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv (2012) 0.86
Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet (2017) 0.81
Validity of a PCI Bleeding Risk Score in patient subsets stratified for body mass index. Open Heart (2015) 0.78
Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: evidence of continuing low use despite consideration of stroke and bleeding risk. Drugs Aging (2013) 0.78
Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World J Cardiol (2014) 0.76
BLEED-Myocardial Infarction Score: Predicting mid-term post-discharge bleeding events. World J Cardiol (2013) 0.75
ACP Journal Club. A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis. Ann Intern Med (2010) 0.75
Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation (2007) 20.44
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet (2005) 11.35
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med (1993) 11.11
Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol (2001) 10.16
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2006) 6.07
A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med (1992) 3.70
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 3.22
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05
Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. J Clin Epidemiol (2004) 2.69
External validity of clinical trials in acute myocardial infarction. Arch Intern Med (2007) 2.14
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Unanswered questions--drug-eluting stents and the risk of late thrombosis. N Engl J Med (2007) 1.70
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J (2006) 1.45
Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J (2007) 1.37
Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke (2008) 1.09
Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care (2002) 0.94
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med (2008) 13.87
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Comparison of registered and published primary outcomes in randomized controlled trials. JAMA (2009) 7.89
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Predictors of new-onset kidney disease in a community-based population. JAMA (2004) 7.45
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med (2014) 5.98
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med (2004) 4.92
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA (2013) 4.81
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med (2008) 4.63